Attributes its 975 Percent Revenue Growth to Widespread Adoption of the CyberKnife(R) Robotic Radiosurgery System
Oct. 20, 2009 (PR Newswire) --
SUNNYVALE, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Accuray Incorporated (Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today that it ranked 155th in the Technology Fast 500(TM), Deloitte LLP's ranking of 500 of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. Rankings are based on percentage of fiscal year revenue growth during the five year period from 2004-2008. Accuray grew 975 percent during this period.
"We are honored to be ranked so highly in a high-profile nationwide listing like the Technology Fast 500," said Euan S. Thomson, Ph.D., president and chief executive officer at Accuray. "We are encouraged that despite difficult economic conditions, hospitals and centers have continued to adopt the CyberKnife technology across the country, allowing for significant growth over the past few years."
"Technology Fast 500(TM) recognizes innovative companies that have broken down barriers to success and defied the odds with their remarkable five-year revenue growth," said Phil Asmundson, Vice Chairman and U.S. Technology, Media and Telecommunications leader, Deloitte LLP. "We congratulate Accuray on this accomplishment."
For more information on the Technology Fast 500(TM) selection criteria and 2009 wining companies, please visit www.fast500.com
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames. Treatments are completed in five or fewer outpatient visits and patients can typically return to normal activities immediately following treatment.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer.
